Disclaimer: We may earn a commission if you make any purchase by clicking our links. Please see our detailed guide here.

Follow us on:

Covid-19 Pushes India’s Pharma Industry Growth to 59% in April

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

Join the Opinion Leaders Network

Join the Techgenyz Opinion Leaders Network today and become part of a vibrant community of change-makers. Together, we can create a brighter future by shaping opinions, driving conversations, and transforming ideas into reality.

The fresh wave of Covid-19 in the country has pushed up sales of medicines and resulted in exponential growth for the pharmaceutical sector.

According to total sales audit data from the world’s largest pharmaceutical market research firm IMS Health, the Indian Pharma Market (IPM) grew 59 percent YoY in April 2021 vs. 16 percent YoY in March 2021 due to the low base effect in April 2020 and a sharp surge in Covid-19-related sales.

On the MAT (moving annual turnover) basis, IPM grew 9.6 percent, primarily driven by pricing growth of 4.3 per cent and new product launch growth of 4.6 per cent. Volume growth was muted at 0.8 per cent.

According to an Emkay Global Financial Services report, all major therapies posted high double-digit growth in April 21.

Within Chronic therapies, Cardiac therapy grew 22 per cent. Similarly, Anti-diabetic therapy grew 10 per cent. VMS (vitamins, minerals and supplements) posted record growth of 80 per cent in April 21 vs 27 per cent in March 21.

The growth in respiratory therapy rebounded sharply at 64 per cent in April 21 after falling for nine consecutive months.

As per the brokerage, DRL grew the fastest at 79 per cent yoy followed by Cipla (77 per cent yoy) and Cadila (53 per cent yoy). Sun Pharma, Lupin and Ipca Labs reported growth of 30-52 per cent yoy.

Other notable outperformers are Glenmark (172 per cent), Aristo (77 per cent), Macleods (69 per cent), and Alkem (82 per cent).

While IPM growth could be strong in the next couple of months, driven by surging Covid-19-related sales and the likely impact of stocking up, we believe growth could normalize as Covid-19 would delay normalization, Emkay said.

Partner With Us

Digital advertising offers a way for your business to reach out and make much-needed connections with your audience in a meaningful way. Advertising on Techgenyz will help you build brand awareness, increase website traffic, generate qualified leads, and grow your business.

Join 10,000+ Fellow Readers

Get Techgenyz’s roundup delivered to your inbox curated with the most important for you that keeps you updated about the future tech, mobile, space, gaming, business and more.


Find Apps

The Ultimate Hub for Discovering Apps Unlock a world of apps: your ultimate hub for exploring and discovering limitless possibilities for on your every needs.

Power Your Business

Solutions you need to super charge your business and drive growth

More from this topic